1,427 reports of this reaction
2.4% of all CANDESARTAN CILEXETIL reports
#6 most reported adverse reaction
DIZZINESS is the #6 most commonly reported adverse reaction for CANDESARTAN CILEXETIL, manufactured by ANI Pharmaceuticals, Inc.. There are 1,427 FDA adverse event reports linking CANDESARTAN CILEXETIL to DIZZINESS. This represents approximately 2.4% of all 59,566 adverse event reports for this drug.
Patients taking CANDESARTAN CILEXETIL who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is a less commonly reported adverse event for CANDESARTAN CILEXETIL, but still significant enough to appear in the safety profile.
In addition to dizziness, the following adverse reactions have been reported for CANDESARTAN CILEXETIL:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 1,427 FDA reports for CANDESARTAN CILEXETIL. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 2.4% of all adverse event reports for CANDESARTAN CILEXETIL, making it a notable side effect.
If you experience dizziness while taking CANDESARTAN CILEXETIL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.